Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types

  • Felip, Eudald|||0000-0002-3812-1313
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Gómez, Maica
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Romeo, Margarita|||0000-0003-1725-8115
  • Morán, Teresa
  • Layos, Laura
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Fernández, Pedro Luis|||0000-0002-8618-4597
  • Mesia, Ricard|||0000-0002-3785-3563
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Ballana, Ester|||0000-0002-5215-7363
  • Margelí, Mireia|||0000-0003-3594-4530
Ample evidence exists connecting dNTP pool dysregulation to cancer and genomic instability. SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. Moreover, it has been proposed that SAMHD1 might fulfill the requirements of a driver gene in tumor development or might promote a so-called mutator phenotype. Here, we show that low SAMHD1 expression tumors show better prognosis in breast, ovarian, and lung advanced cancer. Moreover, low SAMHD1 expression is a positive predictive factor in lung and ovarian cancer treated with platin derivates and/or antimetabolites. In vitro evaluation of its underlying mechanism revealed that SAMHD1 KO cells presented enhanced susceptibility to DNA damage and subsequent induction of apoptosis of tumor cells. Our results provide strong evidence of the clinical importance of SAMHD1, becoming an interesting target for the development of personalized cancer treatments. SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase with important roles in the control of cell proliferation and apoptosis, either through the regulation of intracellular dNTPs levels or the modulation of the DNA damage response. However, SAMHD1's role in cancer evolution is still unknown. We performed the first in-depth study of SAMHD1's role in advanced solid tumors, by analyzing samples of 128 patients treated with chemotherapy agents based on platinum derivatives and/or antimetabolites, developing novel in vitro knock-out models to explore the mechanisms driving SAMHD1 function in cancer. Low (or no) expression of SAMHD1 was associated with a positive prognosis in breast, ovarian, and non-small cell lung cancer (NSCLC) cancer patients. A predictive value was associated with low-SAMHD1 expression in NSCLC and ovarian patients treated with antimetabolites in combination with platinum derivatives. In vitro, SAMHD1 knock-out cells showed increased γ-H2AX and apoptosis, suggesting that SAMHD1 depletion induces DNA damage leading to cell death. In vitro treatment with platinum-derived drugs significantly enhanced γ-H2AX and apoptotic markers expression in knock-out cells, indicating a synergic effect of SAMHD1 depletion and platinum-based treatment. SAMHD1 expression represents a new strong prognostic and predictive biomarker in solid tumors and, thus, modulation of the SAMHD1 function may constitute a promising target for the improvement of cancer therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Felip, Eudald|||0000-0002-3812-1313
  • Castellà Fernández, Eva
  • Quiroga García, Vanesa
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Angelats, Laura
  • Esteve, Anna|||0000-0002-1962-971X
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Fernandez, Pedro Luis
  • Ferrando Díez, Angelica|||0000-0003-0206-7498
  • Pous, Anna
  • Bergamino, Milana|||0000-0002-1091-2711
  • Cirauqui, Beatriz|||0000-0002-0136-8056
  • Romeo, Marga
  • Teruel, Iris|||0000-0002-5563-6562
  • Mesia, Ricard|||0000-0002-3785-3563
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
The lack of validated surrogate biomarkers is still an unmet clinical need in the management of early breast cancer cases that do not achieve complete pathological response after neoadjuvant chemotherapy (NACT). Here, we describe and validate the use of SAMHD1 expression as a prognostic biomarker in residual disease in vivo and in vitro. SAMHD1 expression was evaluated in a clinical cohort of early breast cancer patients with stage II-III treated with NACT. Heterotypic 3D cultures including tumor and immune cells were used to investigate the molecular mechanisms responsible of SAMHD1 depletion through whole transcriptomic profiling, immune infiltration capacity and subsequent delineation of dysregulated immune signaling pathways. SAMHD1 expression was associated to increased risk of recurrence and higher Ki67 levels in post-NACT tumor biopsies of breast cancer patients with residual disease. Survival analysis showed that SAMHD1-expressing tumors presented shorter time-to-progression and overall survival than SAMHD1 negative cases, suggesting that SAMHD1 expression is a relevant prognostic factor in breast cancer. Whole-transcriptomic profiling of SAMHD1-depleted tumors identified downregulation of IL-12 signaling pathway as the molecular mechanism determining breast cancer prognosis. The reduced interleukin signaling upon SAMHD1 depletion induced changes in immune cell infiltration capacity in 3D heterotypic in vitro culture models, confirming the role of the SAMHD1 as a regulator of breast cancer prognosis through the induction of changes in immune response and tumor microenvironment. SAMHD1 expression is a novel prognostic biomarker in early breast cancer that impacts immune-mediated signaling and differentially regulates inflammatory intra-tumoral response. The online version contains supplementary material available at 10.1007/s13402-023-00862-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cetylpyridinium Chloride-Containing Mouthwashes Show Virucidal Activity against Herpes Simplex Virus Type 1

  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Bañó Polo, Manuel|||0000-0002-4840-4480
  • León Berríos, Rubén|||0000-0001-6400-4906
  • Blanc Pociello, Vanessa|||0000-0002-2740-6559
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
The oral cavity is particularly susceptible to viral infections that are self-recovering in most cases. However, complications may appear in severe cases and/or immunocompromised subjects. Cetylpyridinium chloride (CPC)-containing mouthwashes are able to decrease the infectivity of the SARS-CoV-2 virus by disrupting the integrity of the viral envelope. Here, we show that CPC, as the active ingredient contained in commercialized, exerts significant antiviral activity against enveloped viruses, such as HSV-1, but not against non-enveloped viruses, such as HPV. CPC-containing mouthwashes have been used as antiseptics for decades, and thus, they can represent a cost-effective measure to limit infection and spread of enveloped viruses infecting the oral cavity, aiding in reducing viral transmission.